Market capitalization | $21.45b |
Enterprise Value | $23.19b |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | 42.47 |
EV/Sales (TTM) EV/Sales | 5.28 |
P/S ratio (TTM) P/S ratio | 4.89 |
P/B ratio (TTM) P/B ratio | 10.06 |
Revenue growth (TTM) Revenue growth | -1.68% |
Revenue (TTM) Revenue | $4.39b |
Set up alerts on Stock Price, Dividend Yield, Valuation (e.g. P/E or EV/Sales) or Strategy Scores and sit back and relax.
27 Analysts have issued a Illumina forecast:
27 Analysts have issued a Illumina forecast:
Sep '24 |
+/-
%
|
||
Revenue | 4,390 4,390 |
2%
2%
|
|
Gross Profit | 2,808 2,808 |
2%
2%
|
|
EBITDA | 1,364 1,364 |
307%
307%
|
EBIT (Operating Income) EBIT | 974 974 |
1,147%
1,147%
|
Net Profit | -1,585 -1,585 |
41%
41%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Illumina, Inc. engages in the development, manufacturing, and marketing of life science tools and integrated systems for large-scale analysis of genetic variation and function. It operates through Core Illumina segment, which serves customers in the research, clinical and applied markets, and enable the adoption of a variety of genomic solutions. The firm's products include microarray scanners, sequencing reagents, and onsite training selector. Its services include sequencing and microarray services; proactive instrument monitoring; and instrument services, training, and consulting. The company was founded by David R. Walt, John R. Stuelpnagel, Anthony W. Czarnik, Lawrence A. Bock, and Mark S. Chee in April 1998 and is headquartered in San Diego, CA.
Head office | United States |
CEO | Jacob Thaysen |
Employees | 12,010 |
Founded | 1998 |
Website | www.illumina.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.